94 related articles for article (PubMed ID: 21824195)
1. Shortened treatment duration of glucocorticoid-induced skin atrophy in rats.
Schoepe S; Vonk R; Schäcke H; Zollner TM; Asadullah K; Röse L
Exp Dermatol; 2011 Oct; 20(10):853-5. PubMed ID: 21824195
[TBL] [Abstract][Full Text] [Related]
2. Identification of novel in vitro test systems for the determination of glucocorticoid receptor ligand-induced skin atrophy.
Schoepe S; Schäcke H; Bernd A; Zöller N; Asadullah K
Skin Pharmacol Physiol; 2010; 23(3):139-51. PubMed ID: 20051715
[TBL] [Abstract][Full Text] [Related]
3. Superior nuclear receptor selectivity and therapeutic index of methylprednisolone aceponate versus mometasone furoate.
Mirshahpanah P; Döcke WD; Merbold U; Asadullah K; Röse L; Schäcke H; Zollner TM
Exp Dermatol; 2007 Sep; 16(9):753-61. PubMed ID: 17697148
[TBL] [Abstract][Full Text] [Related]
4. Glucocorticoid therapy-induced skin atrophy.
Schoepe S; Schäcke H; May E; Asadullah K
Exp Dermatol; 2006 Jun; 15(6):406-20. PubMed ID: 16689857
[TBL] [Abstract][Full Text] [Related]
5. Effects of a multilamellar emulsion on glucocorticoid-induced epidermal atrophy and barrier impairment.
Ahn SK; Bak HN; Park BD; Kim YH; Youm JK; Choi EH; Hong SP; Lee SH
J Dermatol; 2006 Feb; 33(2):80-90. PubMed ID: 16556273
[TBL] [Abstract][Full Text] [Related]
6. The hairless mouse as a model for study of local and systemic atrophogenic effects following topical application of corticosteroids.
van den Hoven WE; van den Berg TP; Korstanje C
Acta Derm Venereol; 1991; 71(1):29-31. PubMed ID: 1676210
[TBL] [Abstract][Full Text] [Related]
7. Validation of Dermaphot(®) for the assessment of steroid-induced skin atrophy.
Hofmann M; Salgo R; Aschoff R; Luger TA; Meurer M; Bräutigam M; Thaci D
Arch Dermatol Res; 2013 Apr; 305(3):215-21. PubMed ID: 23242470
[TBL] [Abstract][Full Text] [Related]
8. In vivo assessment of the atrophogenic potency of mometasone furoate, a newly developed chlorinated potent topical glucocorticoid as compared to other topical glucocorticoids old and new.
Kerscher MJ; Hart H; Korting HC; Stalleicken D
Int J Clin Pharmacol Ther; 1995 Apr; 33(4):187-9. PubMed ID: 7620686
[TBL] [Abstract][Full Text] [Related]
9. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
Cossmann M; Welzel J
Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
[TBL] [Abstract][Full Text] [Related]
11. In vivo determination of the skin atrophy potential of the super-high-potency topical corticosteroid fluocinonide 0.1% cream compared with clobetasol propionate 0.05% cream and foam, and a vehicle.
Gans EH; Sadiq I; Stoudemayer T; Stoudemayer M; Kligman AM
J Drugs Dermatol; 2008 Jan; 7(1):28-32. PubMed ID: 18246695
[TBL] [Abstract][Full Text] [Related]
12. Effect of RU 486 on the atrophogenic and antiinflammatory effects of glucocorticoids in skin.
Iwasaki K; Mishima E; Miura M; Sakai N; Shimao S
J Dermatol Sci; 1995 Sep; 10(2):151-8. PubMed ID: 8534614
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of anti-inflammatory and atrophogenic effects of glucocorticoids on reconstructed human skin.
Weindl G; Castello F; Schäfer-Korting M
Altern Lab Anim; 2011 May; 39(2):173-87. PubMed ID: 21639680
[TBL] [Abstract][Full Text] [Related]
14. Dorsal skin reactions of hairless dogs to topical treatment with corticosteroids.
Kimura T; Doi K
Toxicol Pathol; 1999; 27(5):528-35. PubMed ID: 10528632
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of beneficial and adverse effects of glucocorticoids on a newly developed full-thickness skin model.
Zöller NN; Kippenberger S; Thaçi D; Mewes K; Spiegel M; Sättler A; Schultz M; Bereiter-Hahn J; Kaufmann R; Bernd A
Toxicol In Vitro; 2008 Apr; 22(3):747-59. PubMed ID: 18249522
[TBL] [Abstract][Full Text] [Related]
16. Topical Mineralocorticoid Receptor Blockade Limits Glucocorticoid-Induced Epidermal Atrophy in Human Skin.
Maubec E; Laouénan C; Deschamps L; Nguyen VT; Scheer-Senyarich I; Wackenheim-Jacobs AC; Steff M; Duhamel S; Tubiana S; Brahimi N; Leclerc-Mercier S; Crickx B; Perret C; Aractingi S; Escoubet B; Duval X; Arnaud P; Jaisser F; Mentré F; Farman N
J Invest Dermatol; 2015 Jul; 135(7):1781-1789. PubMed ID: 25668238
[TBL] [Abstract][Full Text] [Related]
17. [Therapeutic index makes easier the choice of admissible substances. No fear concerning cortisone].
MMW Fortschr Med; 2003 Jul; 145(27-28):64. PubMed ID: 14587199
[No Abstract] [Full Text] [Related]
18. Fluorescence spectroscopy as a tool to detect and evaluate glucocorticoid-induced skin atrophy.
Lemos MC; Correr WR; da Silva de Avó LR; Germano CM; Kurachi C; Polikarpov I; Melo DG
Lasers Med Sci; 2012 Sep; 27(5):1059-65. PubMed ID: 22249456
[TBL] [Abstract][Full Text] [Related]
19. [Comparative animal experiments on epidermal hypoplasia induced by means of topical glucocorticoids].
Weirich EG; Longauer J
Z Hautkr; 1974 Feb; 49(3):91-106. PubMed ID: 4832936
[No Abstract] [Full Text] [Related]
20. Protective effect of topical iodine containing anti-inflammatory drugs against sulfur mustard-induced skin lesions.
Wormser U; Sintov A; Brodsky B; Casillas RP; Nyska A
Arch Toxicol; 2004 Mar; 78(3):156-66. PubMed ID: 14618300
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
